Panelists:
Tom Madden, PhD
President & CEO
Acuitas Therapeutics
Robert Georgantas III, PhD
President and Chief Biotechnology Officer
Providence Therapeutics
Tasuku Kitada, PhD
Co-Founder and President
Strand Therapeutics
Originally Aired: October 19, 2023
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
The effectiveness of mRNA vaccines has sparked significant interest and conversation around novel therapeutics for a range of diseases. The recent award of the 2023 Nobel Prize in Physiology or Medicine to Katalin Karikó and Drew Weissman underscores the transformative potential of mRNA-based therapeutics. Across industry and academia, scientists are working on mRNA-based drugs for conditions such as cystic fibrosis, rheumatic disease, and heart disease as well as vaccines for influenza, HIV, and updated COVID-19 vaccines. There are also efforts to develop personalized mRNA therapeutics in the context of cancer and other conditions. However, there are important challenges that need to be addressed before mRNA-based therapeutics can reach their potential.
In this GEN Learning Lab, our expert panelists discuss the current state of the field, the key challenges hindering widespread adoption of personalized mRNA therapeutics, and what’s needed to overcome them. These challenges include the imperative need for labs to validate the approach and showcase its efficacy; the necessity for scalability in deployment to reach a broader audience; and the importance of ensuring that the technique is viable for both manufacturers and patients. Our panelists will discuss technologies and strategies for mitigating these challenges and helping the field advance.
A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelists.
Produced with support from:
